Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non–small-cell lung cancer

Xia, Tingyi; Li, Hongqi; Sun, Qiong; Wang, Yingjie; Fan, Naibin; Yu, Yu; Li, Ping; Chang, Joe Y.

doi:10.1016/j.ijrobp.2006.04.013

Cited by 264 publications

(158 citation statements)

References 22 publications

Supporting

Mentioning

155

Contrasting

Unclassified

Order By: Relevance

“…Several planning studies have evaluated the performance of VMAT in delivering SBRT. [5][6][7][8] Generally, VMAT planning has a two-stage optimization in which fluence-map-based optimization algorithm calculates optimized fluence maps as a series of discrete beam angles and subsequently, an arc sequencer algorithm converts the fluence maps for multiple fixed-angle delivery to those for arc delivery while optimizing an MLC leaf shape sequence. 9 VMAT uses sweeping leaf sequencer to create an arc treatment plan using an MLC to shape a radiation field so that the delivered dose volume conforms well to a given prescribed dose volume.…”

Section: Introductionmentioning

confidence: 99%

Influence of segment width on plan quality for volumetric modulated arc based stereotactic body radiotherapy

Nithiyanantham¹,

Mani²,

Subramani³

et al. 2014

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Influence of segment width on plan quality for volumetric modulated arc based stereotactic body radiotherapy

Nithiyanantham¹,

Mani²,

Subramani³

et al. 2014

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

“…However, the converse is observed in patients with primary lung cancer associated with central lesions. Therefore, several prescribed doses are necessary to treat NSCLC (McGarry et al 2005;Nagata et al 2005;Timmerman et al 2006;Xia et al 2006;Baumann et al 2009;Shirata et al 2012).…”

Section: Discussionmentioning

confidence: 99%

Dosemetric Parameters Predictive of Rib Fractures after Proton Beam Therapy for Early-Stage Lung Cancer

Ishikawa

Nakamura

Katō

et al. 2016

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Proton beam therapy (PBT) is the preferred modality for early-stage lung cancer. Compared with X-ray therapy, PBT offers good dose concentration as revealed by the characteristics of the Bragg peak. Rib fractures (RFs) after PBT lead to decreased quality of life for patients. However, the incidence of and the risk factors for RFs after PBT have not yet been clarified. We therefore explored the relationship between irradiated rib volume and RFs after PBT for early-stage lung cancer. The purpose of this study was to investigate the incidence and the risk factors for RFs following PBT for early-stage lung cancer. We investigated 52 early-stage lung cancer patients and analyzed a total of 215 irradiated ribs after PBT. Grade 2 RFs occurred in 12 patients (20 ribs); these RFs were symptomatic without displacement. No patient experienced more severe RFs. The median time to grade 2 RFs development was 17 months (range: 9-29 months). The three-year incidence of grade 2 RFs was 30.2%. According to the analysis comparing radiation dose and rib volume using receiver operating characteristic curves, we demonstrated that the volume of ribs receiving more than 120 Gy 3 (relative biological effectiveness (RBE)) was more than 3.7 cm 3 at an area under the curve of 0.81, which increased the incidence of RFs after PBT (P < 0.001). In this study, RFs were frequently observed following PBT for early-stage lung cancer. We demonstrated that the volume of ribs receiving more than 120 Gy 3 (RBE) was the most significant parameter for predicting RFs.

show abstract

“…A phase I trial from Indiana University was one of the first studies to show that SABR at doses up to 60-66 Gy in 3 fractions was feasible and secure in early-stage NSCLC (28). These findings led to prospective trials evaluating the use of SABR in the United States (29), Europe (30,31) and Asia (32)(33)(34). Using various dose and fractionation schemes, tumour control rates were uniformly excellent, ranging from 78 to 97%.…”

Section: Clinical Efficacy Of Sabrmentioning

confidence: 99%

Selenium Protects Retinal Cells from Cisplatin Induced Alterations in Carbohydrate Residues

Akşit¹,

Yazıcı²,

Akşit³

et al. 2015

Balkan Med J

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death worldwide. Approximately 15 to 20% of NSCLC patients present with early or localised disease; this figure is expected to grow with the increased use of low-dose computed tomography (CT) scans for screening (1). The standard treatment for operable stage I NSCLC is lobectomy or pneumonectomy with mediastinal lymphadenectomy. Five-year survival rates of early stage NSCLC patients range between 60 and 80% after surgical resection (2). Despite major developments in minimally-invasive surgical procedures, a substantial proportion of patients are not suitable for surgery due to their comorbidities. Stereotactic body radiation therapy (SBRT) or stereotactic ablative radiotherapy (SABR) has recently emerged as a benchmark of care for medically inoperable patients. SABR is a more concise and well-planned treatment procedure with enhanced local control and survival while minimising treatment cost against conventional radiotherapy.Cancer-specific outcomes of patients in SABR series are generally comparable to surgical series; however, overall survival results are usually reported to be superior in the surgical cohorts because of major differences in the two groups.Approximately one in every three patient dies as a result of comorbidity-related complications instead of cancer in SBRT series. As a result, in patients with operable stage I NSCLC, surgical operation continues to be the benchmark of care. In this review, we plan to summarise the published evidence for the treatment of early stage NSCLC with surgery and SABR. THE SURGICAL MANAGEMENT OF EARLY STAGE NSCLCSurgical resection remains the treatment of choice for patients with stage I or II NSCLC, since it provides the optimal likelihood of cure and long-term survival. Such an operation includes both complete anatomical resection of the tumour and mediastinal lymph node evaluation (3). PREOPERATIVE EVALUATIONPatients with NSCLC who are surgical candidates are often cigarette smokers, which makes them vulnerable to atheroThe management of early-stage Non-small Cell Lung Cancer (NSCLC) has improved recently due to advances in surgical and radiation modalities. Minimallyinvasive procedures like Video-assisted thoracoscopic surgery (VATS) lobectomy decreases the morbidity of surgery, while the numerous methods of staging the mediastinum such as endobronchial and endoscopic ultrasound-guided biopsies are helping to achieve the objectives much more effectively. Stereotactic Ablative Radiotherapy (SABR) has become the frontrunner as the standard of care in medically inoperable early stage NSCLC patients, and has also been branded as tolerable and highly effective. Ongoing researches using SABR are continuously validating the optimal dosing and fractionation schemes, while at the same time instituting its role for both inoperable and operable patients.

show abstract

Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non–small-cell lung cancer

Cited by 264 publications

References 22 publications

Influence of segment width on plan quality for volumetric modulated arc based stereotactic body radiotherapy

Influence of segment width on plan quality for volumetric modulated arc based stereotactic body radiotherapy

Dosemetric Parameters Predictive of Rib Fractures after Proton Beam Therapy for Early-Stage Lung Cancer

Selenium Protects Retinal Cells from Cisplatin Induced Alterations in Carbohydrate Residues

Contact Info

Product

Resources

About